Atropine

Therapeutic indications

Atropine is indicated for:

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Population group: both men and women, only adults (18 years old or older)

Atropine is used in anaesthesia, to reduce the risk of vagal inhibition of the heart and to reduce salivary and bronchial secretions.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intramuscular - 0.3-0.6 mg once

Treatment 2: Intravenous - 0.3-0.6 mg once

Treatment 3: Subcutaneous - 0.3-0.6 mg once

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Population group: both men and women, only minors (0 - 18 years old)

Atropine is used in anaesthesia, to reduce the risk of vagal inhibition of the heart and to reduce salivary and bronchial secretions.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intramuscular - 10-20 ug/kg once

Treatment 2: Intravenous - 10-20 ug/kg once

Treatment 3: Subcutaneous - 10-20 ug/kg once

Poisoning by organo-phosphorous compounds

Population group: both men and women, only minors (0 - 18 years old)

Atropine is used in the treatment of poisoning by certain cholinesterase inhibitors e.g. organo-phosphorous compounds.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 50 ug/kg once

Treatment 2: Intramuscular - 50 ug/kg once

Poisoning by organo-phosphorous compounds

Population group: both men and women, only adults (18 years old or older)

Atropine is used in the treatment of poisoning by certain cholinesterase inhibitors e.g. organo-phosphorous compounds.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 1.2-2 mg once

Treatment 2: Intramuscular - 1.2-2 mg once

Iritis, uveitis

Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

The eye drops are used in the treatment of iritis and uveitis to immobilise the iris and ciliary muscle and to prevent or break down adhesions.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Ophthalmic - 1-3 drops in 1-3 divided doses

Reversal of neuromuscular blockade

Population group: both men and women, only adults (18 years old or older)

Atropine is used in conjunction with neostigmine which is used to reverse the effects of non-depolarising muscle relaxants.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intramuscular - 0.6-1.2 mg once

Refraction

Population group: both men and women, only adults (18 years old or older)

Atropine sulfate is an antimuscarinic agent used as a cycloplegic and mydriatic.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Ophthalmic - 1-2 drop once

Refraction

Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Atropine sulfate is an antimuscarinic agent used as a cycloplegic and mydriatic.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Ophthalmic - 1 drop once

Cholinergic crisis

Population group: both men and women, only adults (18 years old or older)

Treatment of cholinergic crisis of myasthenia gravis.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 0.4-2 mg once

Cardiopulmonary resuscitation

Population group: both men and women, only adults (18 years old or older)

During cardiopulmonary resuscitation to counteract excessive vagal tone on the heart.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Intravenous - 0.2-0.5 mg once

Non ulcer dyspepsia

Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Nonulcer dyspepsia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 0.6-1.2 mg once

Irritable bowel syndrome

Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Irritable colon

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 0.6-1.2 mg once

Diverticular disease

Population group: both men and women, only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Diverticular disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Oral - 0.6-1.2 mg once

Iritis, uveitis

Population group: both men and women, only adults (18 years old or older)

The eye drops are used in the treatment of iritis and uveitis to immobilise the iris and ciliary muscle and to prevent or break down adhesions.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Treatment 1: Ophthalmic - 2-8 drops in 1-4 divided doses

Contraindications

Atropine is contraindicated in the following cases:

Myasthenia gravis

Paralytic ileus, pyloric stenosis, toxic megacolon, severe ulcerative colitis, reflux oesophagitis

at least one of

Paralytic ileus

PS - Pyloric stenosis

Toxic megacolon

Colitis gravis

Reflux esophagitis

Narrow-angle glaucoma

Angle-closure glaucoma

Thyrotoxicosis

Prostatic hypertrophy

Benign prostatic hyperplasia

< Previous: Overview

Next: Precautions >

Atropine

Therapeutic indications

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Treatment 1: Intramuscular - 0.3-0.6 mg once

Treatment 2: Intravenous - 0.3-0.6 mg once

Treatment 3: Subcutaneous - 0.3-0.6 mg once

Prophylaxis of vagal autonomic bradycardia during anaesthesia, salivary and bronchial secretions reduction

Treatment 1: Intramuscular - 10-20 ug/kg once

Treatment 2: Intravenous - 10-20 ug/kg once

Treatment 3: Subcutaneous - 10-20 ug/kg once

Poisoning by organo-phosphorous compounds

Treatment 1: Intravenous - 50 ug/kg once

Treatment 2: Intramuscular - 50 ug/kg once

Poisoning by organo-phosphorous compounds

Treatment 1: Intravenous - 1.2-2 mg once

Treatment 2: Intramuscular - 1.2-2 mg once

Iritis, uveitis

Treatment 1: Ophthalmic - 1-3 drops in 1-3 divided doses

Reversal of neuromuscular blockade

Treatment 1: Intramuscular - 0.6-1.2 mg once

Refraction

Treatment 1: Ophthalmic - 1-2 drop once

Refraction

Treatment 1: Ophthalmic - 1 drop once

Cholinergic crisis

Treatment 1: Intravenous - 0.4-2 mg once

Cardiopulmonary resuscitation

Treatment 1: Intravenous - 0.2-0.5 mg once

Non ulcer dyspepsia

Treatment 1: Oral - 0.6-1.2 mg once

Irritable bowel syndrome

Treatment 1: Oral - 0.6-1.2 mg once

Diverticular disease

Treatment 1: Oral - 0.6-1.2 mg once

Iritis, uveitis

Treatment 1: Ophthalmic - 2-8 drops in 1-4 divided doses

Contraindications

Myasthenia gravis

Paralytic ileus, pyloric stenosis, toxic megacolon, severe ulcerative colitis, reflux oesophagitis

Narrow-angle glaucoma

Thyrotoxicosis

Prostatic hypertrophy

Medication Recommendation

Related medicines